<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333576</url>
  </required_header>
  <id_info>
    <org_study_id>M18-969</org_study_id>
    <nct_id>NCT04333576</nct_id>
  </id_info>
  <brief_title>Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain</brief_title>
  <official_title>A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing
      age. Endometriosis affects daily activities, social relationships, sexuality and sexual
      activity, and mental health. This study will evaluate how well elagolix in combination with
      combined oral contraceptives (COC) works within the body and/or how safe it is compared to
      placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful
      periods) response in participants with endometriosis and associated pain.

      Elagolix is an approved drug for the management of moderate to severe pain associated with
      endometriosis. Participants are randomly put in 1 of 3 groups, called treatment arms. Each
      group receives a different treatment. There is a 1 in 3 chance that participants will be
      assigned to placebo. Adult female participants who still have periods with a diagnosis of
      endometriosis will be enrolled. Around 800 participants will be enrolled in the study at
      multiple sites in the United States, including Puerto Rico.

      Participants will receive oral elagolix or placebo tablets in combination with combined oral
      contraceptive (COC) or placebo capsules for 3 months. All the participants will receive
      elagolix tablets in combination with COC tablets from Month 4 through Month 18.

      There will be higher treatment burden for participants in this trial compared to their
      standard of care. Participants will attend regular visits during the course of the study at a
      hospital or clinic. The effect of the treatment will be checked by medical assessments, blood
      tests, checking for side effects and completing questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 3, 2020</start_date>
  <completion_date type="Anticipated">November 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders Based on Dysmenorrhea (DYS) Pain Scale</measure>
    <time_frame>Month 3</time_frame>
    <description>DYS response is measured by the 4-point Endometriosis Daily Pain Impact Scale (none, mild, moderate, severe) and with stable or decreased analgesic use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders Based on Non-Menstrual Pelvic Pain (NMPP) Pain Scale</measure>
    <time_frame>Month 3</time_frame>
    <description>NMPP response is measured by the 4-point Endometriosis Daily Pain Impact Scale (none, mild, moderate, severe) and with stable or decreased analgesic use.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Elagolix + Combined Oral Contraceptive (COC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive elagolix in combination with COC for 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix + Placebo for COC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive elagolix in combination with placebo for COC for 3 months followed by elagolix in combination with COC for 15 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Elagolix + Placebo for COC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for elagolix in combination with placebo for COC for 3 months followed by elagolix in combination with COC for 15 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Tablet:Oral</description>
    <arm_group_label>Elagolix + Combined Oral Contraceptive (COC)</arm_group_label>
    <arm_group_label>Elagolix + Placebo for COC</arm_group_label>
    <arm_group_label>Placebo for Elagolix + Placebo for COC</arm_group_label>
    <other_name>ABT-620</other_name>
    <other_name>Orilissa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Oral Contraceptive (COC)</intervention_name>
    <description>Tablet:Oral</description>
    <arm_group_label>Elagolix + Combined Oral Contraceptive (COC)</arm_group_label>
    <arm_group_label>Elagolix + Placebo for COC</arm_group_label>
    <arm_group_label>Placebo for Elagolix + Placebo for COC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Elagolix</intervention_name>
    <description>Tablet:Oral</description>
    <arm_group_label>Placebo for Elagolix + Placebo for COC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for COC</intervention_name>
    <description>Capsule:Oral</description>
    <arm_group_label>Elagolix + Placebo for COC</arm_group_label>
    <arm_group_label>Placebo for Elagolix + Placebo for COC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Oral Contraceptive (COC)</intervention_name>
    <description>Capsule:Oral</description>
    <arm_group_label>Elagolix + Combined Oral Contraceptive (COC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented surgical confirmation of endometriosis and associated moderate to severe
             pain.

          -  Participants must agree to use dual non-hormonal methods of contraception consistently
             during washout (if applicable), screening, and 3-month double-blind placebo-controlled
             treatment periods of the study.

          -  Participant, in the investigator's opinion must be an appropriate candidate to receive
             combined oral contraceptives (COCs).

        Exclusion Criteria:

          -  Pregnant or breastfeeding or planning a pregnancy until completion of the study.

          -  Surgical history of hysterectomy or bilateral oophorectomy.

          -  Participant has osteoporosis or other metabolic bone disease or clinically significant
             gynecological findings from Screening.

          -  Participant has any other active chronic pain condition that would interfere with
             their assessment of endometriosis-related pain.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group /ID# 217062</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC /ID# 218044</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC /ID# 217166</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235-3430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown, Pearson, Guepet Gynecology /ID# 217143</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mobile, Ob-Gyn, P.C. /ID# 217135</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mesa Obstetricians and Gynecol /ID# 217092</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unity Health- Searcy Medical Center /ID# 217050</name>
      <address>
        <city>Searcy</city>
        <state>Arkansas</state>
        <zip>72143-4802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Womens Health Care /ID# 217297</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Women's Health Institute /ID# 217150</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James A. Simon, MD, PC /ID# 218116</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group /ID# 218524</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Physiology Associates /ID# 217061</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocean Blue Med Research Ctr /ID# 217286</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research /ID# 217249</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Associates of Orlando /ID# 218114</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Care Clin. Res., LLC /ID# 217264</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCP Clinical Research, LLC /ID# 217232</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609-4044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida /ID# 217146</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virtus Research Consultant,LLC /ID# 217052</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Women's Research Inst /ID# 217303</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affinity Clinical Research /ID# 217226</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Beginnings Obstetrics &amp; Gynecology /ID# 217227</name>
      <address>
        <city>Sycamore</city>
        <state>Illinois</state>
        <zip>60178-3119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics /ID# 217144</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTC Research /ID# 217051</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRN Professional Research Network of Kansas, LLC /ID# 218040</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Ctr /ID# 217093</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management, LLC - Covington /ID# 217054</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management, LLC - Covington /ID# 217291</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research A /ID# 218028</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Clinic /ID# 217205</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71118-3133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Women's Care - Hagerstown /ID# 218167</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740-6555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NECCR Fall River LLC /ID# 217108</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720-2972</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research - Fall River /ID# 217116</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group,Inc /ID# 217099</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COLUMBIA University Medical Center /ID# 217113</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington LLC /ID# 217097</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Resea /ID# 217132</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Inquest Center Ltd /ID# 217961</name>
      <address>
        <city>Beavercreek</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OB/GYN Associates of Erie /ID# 217242</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507-1423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vista Clinical Research /ID# 217151</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Research /ID# 217069</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485-7539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research /ID# 217045</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Memphis Associates, LLC /ID# 218022</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119-3895</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center /ID# 217048</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8575</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signature Gyn Services /ID# 217299</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willowbend Health and Wellness - Frisco /ID# 217354</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas (UT) Health Women's Research Center at Memorial City /ID# 217362</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024-2515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victorium Clinical Research /ID# 217261</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Reproductive Medicin /ID# 217241</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc. (HRHR) /ID# 217063</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LL /ID# 217359</name>
      <address>
        <city>North Chesterfield</city>
        <state>Virginia</state>
        <zip>23235-4722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James River Ob-Gyn /ID# 217149</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225-4017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidewater Clinical Research /ID# 217152</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rodriguez-Ginorio, San Juan /ID# 217233</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 217235</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>Elagolix</keyword>
  <keyword>Combined oral contraceptives (COC)</keyword>
  <keyword>Orilissa</keyword>
  <keyword>Dysmenorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

